Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiora Pharmaceuticals (KPRX) Cash from Operations (2016 - 2025)

Kiora Pharmaceuticals (KPRX) has disclosed Cash from Operations for 11 consecutive years, with 1273088.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Cash from Operations fell 238.37% year-over-year to 1273088.0, compared with a TTM value of 10033079.0 through Sep 2025, down 221.91%, and an annual FY2024 reading of 8559115.0, up 189.56% over the prior year.
  • Cash from Operations was 1273088.0 for Q3 2025 at Kiora Pharmaceuticals, up from 3803434.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 13624855.0 in Q1 2024 and bottomed at 3803434.0 in Q2 2025.
  • Average Cash from Operations over 5 years is 1392895.81, with a median of 2575696.0 recorded in 2021.
  • The sharpest move saw Cash from Operations skyrocketed 543.87% in 2024, then tumbled 238.37% in 2025.
  • Year by year, Cash from Operations stood at 2919668.0 in 2021, then grew by 2.99% to 2832386.0 in 2022, then increased by 8.86% to 2581341.0 in 2023, then increased by 12.74% to 2252358.0 in 2024, then soared by 43.48% to 1273088.0 in 2025.
  • Business Quant data shows Cash from Operations for KPRX at 1273088.0 in Q3 2025, 3803434.0 in Q2 2025, and 2704199.0 in Q1 2025.